Results 11 to 20 of about 2,196,135 (231)

Atherectomy followed by drug-coated balloon angioplasty for below knee lesions in diabetic patients

Cirugía y Cirujanos, 2022
Objective: The aim of this study was to compare the long-term outcomes of below the knee revascularization with percutaneous atherectomy followed by drug-coated balloon and revascularization with drug-coated balloon alone for symptomatic diabetic ...
Orhan Rodoplu, Zafer Er, Ibrahim Erdinc, Cuneyd Ozturk   +3 more
doaj   +1 more source

A Multicenter Randomized Trial Assessing ZENFlow Carrier-Free Drug-Coated Balloon for the Treatment of Femoropopliteal Artery Lesions

Frontiers in Cardiovascular Medicine, 2022
Backgrounds and ObjectivesDrug-coated balloons (DCBs) have shown promising benefits in improving the outcomes for patients with peripheral artery disease.
Leng Ni, Wei Ye, Lan Zhang, Xing Jin, Chang Shu, Jin-song Jiang, Mu Yang, Dan-ming Wu, Ming Li, Guan-feng Yu, Jun Yang, Jian-hua Huang, Xiao-bai Wang, Xiao-qiang Li, Wei-liang Jiang, Zhi-qun Wu, Chang-wei Liu   +16 more
doaj   +1 more source

Effectiveness of drug-coated balloon in treating real-world femoropopliteal lesions: A cohort study

Vascular Investigation and Therapy, 2023
BACKGROUND: The drug-coated balloon is superior to angioplasty for simple femoropopliteal lesions in clinical trials. The evidence on the effectiveness of Acotec drug-coated balloon in treating complex femoropopliteal lesions in the real world is ...
Guochen Niu, Bihui Zhang, Ziguang Yan, Yinghua Zou, Xiaoqiang Tong, Min Yang   +5 more
doaj   +1 more source

Drug-coated balloon dilation for female urethral stricture

Urology Case Reports
Drug-coated balloon dilation (DCB) has demonstrated long-term efficacy for male patients with urethral stricture disease (USD); however, the role of DCB for female USD remains unknown.
Hannah S. Thomas, Noah Stern, Sarah Neu, Sender Herschorn   +3 more
doaj   +2 more sources

3D modelling of drug-coated balloons for the treatment of calcified superficial femoral arteries.

PLoS ONE, 2021
Background/objectivesDrug-coated balloon therapy for diseased superficial femoral arteries remains controversial. Despite its clinical relevance, only a few computational studies based on simplistic two-dimensional models have been proposed to ...
Monika Colombo, Anna Corti, Scott Berceli, Francesco Migliavacca, Sean McGinty, Claudio Chiastra   +5 more
doaj   +1 more source

DCB combined with provisional DES implantation in the treatment of De Novo Medina 0,1,0 or 0,0,1 left main coronary bifurcation lesions: A proof-of-concept study

Anatolian Journal of Cardiology, 2022
Objective: To investigate the safety and efficacy of a percutaneous revascularization strategy that is based on the use of drug-coated balloon for the treatment of patients with acute coronary syndrome and de novo Medina type 0,1,0 or 0,0,1 left main ...
Emrah Erdoğan, Zheng Li, Yong-xiang Zhu, Vincenzo Tufaro, Si-li Feng, Qian Li, Li Liang, Shang Chang, Ling-tong Bu, Bing Liu, Qi-hua Zhou, Nathan A. L. Yap, Christos V. Bourantas, Yao-jun Zhang   +13 more
doaj   +1 more source

Safety and Efficacy of an Innovative Everolimus-Coated Balloon in a Swine Coronary Artery Model

Life, 2023
Background: Drug-coated balloons have been used as a non-stenting treatment in coronary and peripheral artery disease. Until recently, only sirolimus- and paclitaxel-coated balloons have been investigated in clinical trials.
Christos S. Katsouras, Alexandros Tousis, Georgios Vasilagkos, Arsen Semertzioglou, Athanassios Vratimos, Ioanna Samara, Georgia Karanasiou, Vasileios S. Loukas, Grigorios Tsigkas, Dimitrios Fotiadis, Lampros K. Michalis, Periklis Davlouros, Anargyros N. Moulas   +12 more
doaj   +1 more source

Temporal reverse flow by proximal femoral artery occlusion during drug-coated balloon dilatation: a technique to minimize downstream particle embolization and systemic adverse effects

Journal of Vascular Surgery Cases and Innovative Techniques, 2021
Downstream paclitaxel particle embolization for nonhealing ischemic ulcers and systemic adverse effects caused by a paclitaxel drug-coated balloon are of concern, and safety measures to prevent these adverse risks are needed.
Masayoshi Kimura, MD, Jun Shiraishi, MD, PhD, Masayuki Hyogo, MD, Takahisa Sawada, MD, PhD   +3 more
doaj   +1 more source

Technical success, clinical efficacy, and insight into the causes of restenosis after the percutaneous coronary intervention of de novo coronary artery lesions using a paclitaxel-coated balloon with citrate ester excipient

Frontiers in Cardiovascular Medicine, 2022
ObjectivesThe aim of this all-comers registry study was to investigate the technical success, clinical efficacy, and safety of a drug-coated balloon (DCB) with paclitaxel combined with citrate ester excipient (CEE) in percutaneous coronary intervention ...
Jerry Tervo, Jussi M. Kärkkäinen, Tuomas T. Rissanen   +2 more
doaj   +1 more source

Twisting of the Ranger drug‐coated balloon for treating superficial femoral artery disease

Clinical Case Reports, 2022
Paclitaxel‐coated balloons have demonstrated improved efficacy compared with uncoated percutaneous transluminal angioplasty for femoropopliteal artery disease. While applying a long balloon, twisting of the balloon can be occurred.
Su Hong Kim, Jong Hyun Choi, Bo Won Kim, Sang Hee Kim   +3 more
doaj   +1 more source